Loading
Geneplus-Beijing's personalised blood test for leftover cancer in bowel, breast and lung cancer, which labels each tracked mutation as present in all tumour cells or only some.
Geneplus-Beijing described the assay in MedComm in 2025 (Liu et al.): up to 20 variants chosen from tumour profiling, combined with a cancer-type fixed panel, with a stated sample-level limit of detection as low as 0.005 per cent and 100 per cent specificity. Applied to colorectal, breast and lung cancer, it predicted postoperative recurrence before imaging by a median of 112 days in breast cancer and 83 days in lung cancer.
It is the one published assay in this group that labels the tracked variants as clonal or subclonal, and in its data clonal mutations carried more prognostic value than subclonal ones. That is research output, not a reported clinical field.
Comprehensive genomic profiling of the tumour selects up to 20 top-ranked variants for a personalised panel, which is combined with a tumour-naive fixed panel for the cancer type and sequenced deeply in plasma.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Geneplus personalised MRD assay" OR ABSTRACT:"Geneplus personalised MRD assay" OR TITLE:"Geneplus tumour-informed MRD assay" OR ABSTRACT:"Geneplus tumour-informed MRD assay" OR TITLE:"Geneplus ctDNA-MRD assay" OR ABSTRACT:"Geneplus ctDNA-MRD assay") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Geneplus personalised MRD assay, not a curated reading list.
Shares brPROPHET, Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA) and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/